Travaux scientifiques

Prof. Dr. Ömer Fatih Ölmez

164 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

    Cerrahpasa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26082 Texte intégral en libre accèsSource : OpenAlex

  2. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Texte intégral en libre accèsSource : OpenAlex

  3. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Texte intégral en libre accèsSource : OpenAlex

  4. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Texte intégral en libre accèsSource : OpenAlex

  5. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  6. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-7-10 Texte intégral en libre accèsSource : OpenAlex

  7. Investigation of Predictive and Prognostic Factors in Metastatic Renal Cell Carcinoma (mRCC) Patients Receiving First-line Treatment: A Retrospective Single-center Experience

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.78942 Texte intégral en libre accèsSource : OpenAlex

  8. Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61177-3 PMID 42414499 Texte intégral en libre accèsSource : OpenAlex

  9. Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

    European Journal of Cancer Care, 2026

    DOI 10.48130/ejcc-0026-0010 Source : OpenAlex

  10. Clinicopathologic Features of NRG1 Fusion‐Positive Non‐Small Cell Lung Cancer

    Genes, Chromosomes and Cancer, 2026

    DOI 10.1002/gcc.70170 PMID 42706502 Texte intégral en libre accèsSource : ORCID

  11. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47351-7 PMID 41933152 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  12. Abstract PS4-10-28: Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-10-28 Source : OpenAlex

  13. Reconsidering the Value of Baseline PET/CT in Early-Stage Breast Cancer: Evidence for Selective Use from the MF21-02 Multicenter Study

    Breast Care, 2026

    DOI 10.1159/brc/abrag012 Source : OpenAlex

  14. Claudin 18.2, IDH1, and neutrophil-to-lymphocyte ratio as prognostic biomarkers in unresectable pancreatic ductal adenocarcinoma receiving first-line chemotherapy

    Biomolecules and Biomedicine, 2026

    DOI 10.17305/bb.2026.14093 PMID 41954483 Texte intégral en libre accèsSource : OpenAlex

  15. A Composite Histopathologic Invasion Score Predicts Lymph Node Metastasis in Gastric Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176509 PMID 42739515 Texte intégral en libre accèsSource : OpenAlex

  16. Comparative safety of concurrent adjuvant trastuzumab emtansine vs trastuzumab with radiotherapy in HER2-positive early breast cancer

    The Oncologist, 2026

    DOI 10.1093/oncolo/oyag372 PMID 42768455 Texte intégral en libre accèsSource : OpenAlex

  17. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Texte intégral en libre accèsSource : OpenAlex

  19. Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    Medicina, 2025

    DOI 10.3390/medicina61030380 PMID 40142191 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  20. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14072264 PMID 40217714 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy

    Diagnostics, 2025

    DOI 10.3390/diagnostics15081048 PMID 40310425 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  22. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14092937 PMID 40363968 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

    Medicina, 2025

    DOI 10.3390/medicina61020340 PMID 40005456 Texte intégral en libre accèsSource : OpenAlex

  24. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

    Ege Tıp Dergisi, 2025

    DOI 10.19161/etd.1569835 Texte intégral en libre accèsSource : OpenAlex

  25. The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186536 PMID 41010740 Texte intégral en libre accèsSource : OpenAlex

  26. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

    Cancers, 2025

    DOI 10.3390/cancers17091592 PMID 40361516 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  27. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

    Medicina, 2025

    DOI 10.3390/medicina61010123 PMID 39859105 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

    The Lancet Respiratory Medicine, 2025

    DOI 10.1016/s2213-2600(25)00209-7 PMID 40983066 1 citation (Europe PMC) Source : OpenAlex

  29. The Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    2025

    DOI 10.20944/preprints202508.0265.v1 Texte intégral en libre accèsSource : ORCID

  30. The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy

    2025

    DOI 10.20944/preprints202503.1873.v1 Texte intégral en libre accèsSource : ORCID

  31. Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review

    Medicina, 2025

    DOI 10.3390/medicina61020302 PMID 40005418 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  32. The Role of Pre-Treatment Inflammatory Biomarkers in Predicting Tumor Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

    Medicina, 2025

    DOI 10.3390/medicina61050865 PMID 40428824 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  33. Cytotoxic Lesion of the Corpus Callosum Associated with 5-Fluorouracil: A Case Report and Review of Literature

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-5 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  34. CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e15095 Texte intégral en libre accèsSource : OpenAlex

  35. Inflammation-Related Parameters in Lung Cancer Patients Followed in the Intensive Care Unit

    Healthcare, 2025

    DOI 10.3390/healthcare14010039 PMID 41516970 Texte intégral en libre accèsSource : OpenAlex

  36. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Source : OpenAlex

  37. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

    Current Oncology, 2024

    DOI 10.3390/curroncol31090384 PMID 39330012 Texte intégral en libre accèsSource : OpenAlex

  38. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

    Cancers, 2024

    DOI 10.3390/cancers16193389 PMID 39410009 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  39. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  40. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

    Medicine, 2024

    DOI 10.1097/md.0000000000037972 PMID 38787994 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  41. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

    Current Problems in Cancer, 2024

    DOI 10.1016/j.currproblcancer.2024.101102 PMID 38735211 2 citations (Europe PMC) Source : OpenAlex

  42. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2337261 PMID 38568074 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  43. Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024

    DOI 10.32708/uutfd.1515582 Texte intégral en libre accèsSource : OpenAlex

  44. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

    Medicina, 2024

    DOI 10.3390/medicina60122103 PMID 39768982 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  45. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2314830 PMID 38351652 2 citations (Europe PMC) Source : OpenAlex

  46. Torasik Rayoterapi Sonrası Gelişen Radyasyon Pnömoniti Hastalarında Prognostik ve Prediktif Faktörlerin Analizi: Retrospektif Tek Merkez Deneyimi

    Ege Tıp Bilimleri Dergisi, 2024

    DOI 10.33713/egetbd.1527615 Texte intégral en libre accèsSource : OpenAlex

  47. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

    Japanese Journal of Clinical Oncology, 2024

    DOI 10.1093/jjco/hyae002 PMID 38271177 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  48. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

    Cancers, 2024

    DOI 10.3390/cancers16183213 PMID 39335184 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  49. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102228 PMID 39461025 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  50. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102163 PMID 39126823 1 citation (Europe PMC) Source : ORCID